This report by the Tony Blair Institute for Global Change explores the scientific advancements that aim to extend both lifespan and healthspan, ensuring that longer lives are also healthier. While modern medicine has increased life expectancy, many people spend their later years in poor health. Researchers are now focusing on the biology of ageing itself, rather than just treating age-related diseases individually. By targeting the fundamental mechanisms of ageing, scientists hope to delay the onset of chronic illnesses and extend healthy life.

Innovations in longevity research, such as senolytic drugs, gene editing, and AI-driven discoveries, offer promising pathways to slowing ageing. Drugs like metformin and rapamycin are being tested for their potential to combat age-related decline, while regenerative medicine is exploring ways to repair or replace damaged tissues and organs. Advances in genomics and personalized medicine could further help tailor treatments to individuals, enhancing both quality and length of life.

The report argues that addressing ageing is not just a medical challenge but also an economic necessity. As populations age, the strain on healthcare and pension systems grows, making it crucial for governments to invest in longevity research. Policymakers are urged to set ambitious targets, fund cutting-edge research, and support clinical trials to accelerate progress.

Ultimately, the goal is to transform ageing from an inevitable decline into a manageable process, allowing people to remain healthier for longer. With the right investment and innovation, the dream of significantly extending healthspan—and not just lifespan—could become a reality.